Clinical Trials Logo

Filter by:
NCT ID: NCT05021900 Completed - Clinical trials for Metastatic Breast Cancer

Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer

Start date: October 13, 2021
Phase: Phase 2
Study type: Interventional

Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic breast cancer.

NCT ID: NCT05015764 Completed - Heart Failure Clinical Trials

Reprieve Cardiovascular System for the Treatment of Subjects With Acute Decompensated Heart Failure Mechanistic Study

Start date: April 12, 2021
Phase: N/A
Study type: Interventional

Reprieve Cardiovascular System for the Treatment of Subjects with Acute Decompensated Heart Failure Mechanistic Study

NCT ID: NCT04985812 Completed - Clinical trials for Rheumatoid Arthritis

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

Start date: October 18, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA).

NCT ID: NCT04984993 Completed - Clinical trials for Erectile Dysfunction

Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

Start date: September 14, 2021
Phase: Phase 3
Study type: Interventional

An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected to participate for up to 30 weeks. Eligible patients will be randomised to receive either MED3000 gel or tadalafil (5 mg) tablets in a 1:1 ratio.

NCT ID: NCT04934072 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

Start date: July 5, 2021
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to demonstrate equivalent efficacy of FKS518 to US-licensed Prolia in women with postmenopausal osteoporosis (PMO). Participants will be randomized at the beginning of the Double-blind Core Treatment Period (Baseline to Week 52) to receive either FKS518 or US-licensed Prolia on Day 1, and then every 26 weeks for up to 52 weeks. At the beginning of the Double-blind Transition Period (Week 52 to Week 78), participants who received US-licensed Prolia will be re-randomized to either continue receiving US-licensed Prolia every 26 weeks for up to 78 weeks, or switch to receive FKS518 every 26 weeks for up to 78 weeks. Participants who were randomized to receive FKS518 at the beginning of the Double-blind Core Treatment Period will continue to receive this treatment during the Double-blind Transition Period. For Marketing Authorization Application (MAA) in the EU and European Economic Area (EEA) only: The primary objective is to demonstrate equivalent efficacy and pharmacodynamics of the proposed biosimilar denosumab FKS518 to US-Prolia in women with PMO.

NCT ID: NCT04930042 Completed - Psoriasis Clinical Trials

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Start date: June 3, 2021
Phase: Phase 3
Study type: Interventional

Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis

NCT ID: NCT04856930 Completed - Clinical trials for Hidradenitis Suppurativa

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa

Start date: July 7, 2021
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of Imsidolimab (ANB019) in Subjects with Hidradenitis Suppurativa

NCT ID: NCT04795557 Completed - Covid19 Clinical Trials

Efficacy of Adaptogens in Patients With Long COVID-19

Start date: April 19, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this clinical trial of a fixed combination of standardized extracts from Rhodiola rosea roots, Schisandra chinensis berry and Eleutherococcus senticosus root (ADAPT-232) in COVID-19 patients is to demonstrate possible efficacy of adjuvant treatment with ADAPT-232 in decreasing the duration of the convalescence, alleviation of fatigue, headache, attention deficit, difficult and rapid respiration, depression, anxiety and other symptoms of Long COVID-19 during rehabilitation period.

NCT ID: NCT04792385 Completed - Safety Clinical Trials

Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents

Start date: December 28, 2020
Phase: Phase 3
Study type: Interventional

To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4) 15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants between the age of 12 and 17 years + 2 months.

NCT ID: NCT04775264 Completed - Atrial Fibrillation Clinical Trials

Safety and Feasibility of Atrial Deganglionation as Adjunctive Therapy for AF

Neural-AF
Start date: May 17, 2021
Phase: N/A
Study type: Interventional

A prospective, single arm, multi-center exploratory study of safety and feasibility in the treatment of patients undergoing cardiothoracic surgery.